A Phase 1, Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Fecal Pharmacokinetics of Orally Administered BX002-A in Healthy Adult Individuals
Latest Information Update: 14 Jan 2022
At a glance
- Drugs BX 002 (Primary) ; Esomeprazole
- Indications Inflammatory bowel diseases; Primary sclerosing cholangitis
- Focus Adverse reactions; First in man
- Sponsors BiomX
Most Recent Events
- 15 Nov 2021 Results assessing the safety and tolerability of orally administered BX002-A cocktail of bacteriophages targeting KP2H7 and assessed phage viability after passage through the gastrointestinal tract, presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases.
- 03 Feb 2021 Status changed from active, no longer recruiting to completed.
- 02 Feb 2021 According to a BiomX media release, Phase 1b/2 trial of BX003 for the reduction of K. pneumonia will start based on data from this trial.